Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
#YonhapInfomax #YuhanCorp #JohnsonAndJohnson #Leclaza #Rybrevant #NonSmallCellLungCancer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=90019
Yuhan Corp. and Johnson & Johnson Launch Joint Domestic Promotion for 'Leclaza–Rybrevant' Combination Therapy
Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
Yuhan Corp. Reports 55.7% Drop in Q3 Operating Profit—Impact of Milestone Absence (Comprehensive)
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit due to the absence of Leclaza milestone payments, with results missing market expectations.
Yuhan Corp. Receives $45 Million Milestone Payment for 'Leclaza' Following Commercial Launch in China
Yuhan Corp. will receive a $45 million milestone payment from Janssen Biotech after the commercial launch of Leclaza in China, marking a key step in its global expansion strategy.
Yuhan Corp. Marks 99th Anniversary—Aims to Join Global Top 50 Pharmaceutical Companies
Yuhan Corp. celebrates its 99th anniversary, unveiling plans to become a global top 50 pharmaceutical company through enhanced R&D and sustainable management.
Yuhan Corp. will receive a $15 million (20.7 billion won) milestone payment from Janssen Biotech after its lung cancer drug Leclaza was officially launched in Japan, marking a key step in the drug's global commercialization.
#YonhapInfomax #YuhanCorp #Leclaza #JanssenBiotech #MilestonePayment #JapanLaunch #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=65606
Yuhan to Receive 20.7 Billion Won in Royalties as Leclaza Launches Commercially in Japan
Yuhan Corp. will receive a $15 million (20.7 billion won) milestone payment from Janssen Biotech after its lung cancer drug Leclaza was officially launched in Japan, marking a key step in the drug's global commercialization.
Yuhan Corporation's Lung Cancer Drug Leclaza Combination Therapy Approved as First-Line Treatment in Japan
Yuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry
Yuhan Corporation CEO Jo Wook-je - 'All-out Effort to Enhance Shareholder Value'
Yuhan Corporation CEO Jo Wook-je pledges to enhance shareholder value, highlighting FDA approval for Leclaza and record-breaking net sales at annual shareholders' meeting
Yonhap Infomax News